黄山胶囊(002817) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥101,310,277.27, a decrease of 2.68% compared to ¥104,095,453.39 in the same period last year[3] - Net profit attributable to shareholders increased by 29.36% to ¥13,969,880.23 from ¥10,799,475.10 year-on-year[3] - Net profit for Q1 2022 reached ¥13,929,428.55, representing an increase of 36.5% from ¥10,244,482.70 in Q1 2021[18] - The total comprehensive income for the parent company attributable to owners was CNY 13,960,700.25, compared to CNY 10,813,442.19 in the previous period, reflecting an increase of approximately 28.5%[19] Cash Flow - The net cash flow from operating activities rose by 59.19% to ¥23,600,068.31, compared to ¥14,824,838.69 in the previous year[3] - The cash inflow from operating activities totaled CNY 73,910,120.63, while cash outflow was CNY 50,310,052.32, resulting in a net cash flow of CNY 23,600,068.31[21] - The net cash flow generated from operating activities was CNY 23,600,068.31, up from CNY 14,824,838.69 in the previous period, indicating a growth of about 59.8%[21] - The net increase in cash and cash equivalents decreased by 2405.69% to a net decrease of ¥11,378.32 million, primarily due to reduced cash flows from investing and financing activities[8] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,084,560,420.74, reflecting a 2.92% increase from ¥1,053,820,293.60 at the end of the previous year[3] - Total assets as of the end of Q1 2022 were ¥1,084,560,420.74, an increase from ¥1,053,820,293.60 at the beginning of the year[14] - Total liabilities increased to ¥260,667,000.55 from ¥243,844,826.99 at the beginning of the year, reflecting a rise of 6.9%[15] Earnings and Profitability - Basic earnings per share increased by 40.00% to ¥0.07 from ¥0.05 in the same period last year[3] - Basic and diluted earnings per share were both CNY 0.07, an increase from CNY 0.05 in the previous period, representing a growth of 40%[19] - The company reported a gross profit margin of approximately 12.3% for Q1 2022, compared to 10.5% in the same period last year[18] Investment and Expenditures - The company reported a significant increase in trading financial assets, which rose by 193.17% to ¥12,583.14 million due to investments in bank wealth management products[6] - The company incurred a cash outflow of CNY 236,249,003.97 for investment activities, compared to CNY 39,326,110.73 in the previous period, reflecting a strategic increase in capital expenditures[23] - The company reported a net cash outflow from investing activities of CNY -130,754,044.31, compared to CNY -36,398,597.41 in the previous period, showing a significant increase in investment expenditures[23] - The total cash inflow from investment activities was CNY 105,494,959.66, significantly higher than CNY 2,927,513.32 in the previous period, indicating a substantial increase in investment returns[22] Operational Efficiency - The company's government subsidies recognized in the current period amounted to ¥3,613,420.79, contributing to the increase in other income[5] - The company experienced a 30.91% increase in accounts receivable, totaling an increase of ¥2,503.32 million, indicating delayed collection of receivables[6] - Accounts receivable increased to ¥106,032,972.69, up 30.5% from ¥80,999,747.90 at the beginning of the year[13] - Research and development expenses for Q1 2022 were ¥3,869,928.41, compared to ¥3,602,953.61 in Q1 2021, indicating an increase of 7.4%[18] Future Outlook - The company plans to continue expanding its market presence and invest in new product development to drive future growth[18]